Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism

Capital Medical University

Status

Unknown

Conditions

Neuromyelitis Optica

Gene

Glucocorticoid Resistance

Treatments

Drug: Methylprednisolone

Study type

Observational

Funder types

Other

Identifiers

NCT04601142

BeijingTH-YLJD-202001

Details and patient eligibility

About

Aims of this study are to observe the correlation between ABCB1、VDR、TBX21、NR3C1 and other gene polymorphisms and the effect of glucocorticoid shock therapy on neuromyelitis optica. Investigators plan to include patients with neuromyelitis optica who will receive glucocorticoid shock therapy prospectively. The patients are divided into glucocorticoid sensitive (GS) group and glucocorticoid resistance (GR) group according to the change of central vision after treatment. Patients' clinical data will be collected and blood samples are needed for single nucleotide polymorphism (SNP) typing test. Through statistical analysis, the data differences between GS group and GR group were compared, and the effects of clinical indexes and gene polymorphisms on the efficacy of glucocorticoid shock therapy in the treatment of neuromyelitis optica should be analyzed.

Enrollment

350 estimated patients

Sex

All

Ages

16 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of neuromyelitis optica
Chinese Han nationality, gender is unlimited;
Must be able to accept methylprednisolone pulse therapy

Exclusion criteria

Other optic nerve diseases, such as ischemic, compressive, invasive, traumatic, toxic and nutritional metabolic, hereditary optic neuropathy;
Visual path and central lesion on optic chiasma;
Other eye diseases, such as anterior segment lesions, retinopathy, macular lesions, ametropia, glaucoma, etc;
Non-organic visual impairment;
Treated with glucocorticoid in two weeks.